Share on StockTwits

Ovascience (NASDAQ:OVAS) Director Richard Aldrich purchased 2,000 shares of the stock in a transaction that occurred on Monday, June 30th. The shares were purchased at an average cost of $9.16 per share, for a total transaction of $18,320.00. Following the purchase, the director now directly owns 526,445 shares of the company’s stock, valued at approximately $4,822,236. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

A number of research firms have recently commented on OVAS. Analysts at HC Wainwright reiterated a “buy” rating on shares of Ovascience in a research note on Monday, May 12th. Analysts at Oppenheimer initiated coverage on shares of Ovascience in a research note on Tuesday, April 29th. They set an “outperform” rating and a $11.00 price target on the stock.

Shares of Ovascience (NASDAQ:OVAS) opened at 9.44 on Friday. Ovascience has a one year low of $5.509 and a one year high of $15.75. The stock’s 50-day moving average is $8.13 and its 200-day moving average is $8.90. The company’s market cap is $220.4 million.

Ovascience (NASDAQ:OVAS) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.05. On average, analysts predict that Ovascience will post $-1.92 earnings per share for the current fiscal year.

OvaScience, Inc, is a life science company developing products to improve the treatment of female infertility based on recent scientific discoveries about the existence of egg precursor cells.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.